Barclays raised its price target from $32 to $35, but kept its Equal-Weight rating. The higher target is positive, yet the unchanged rating and lack of company news leave no clear change in ACHC's outlook.
The higher target shows Barclays sees more possible value in ACHC shares. Keeping the same rating shows it did not make a stronger call. The report gives no new company results, so it does not clearly change ACHC's outlook.
Follow Acadia Healthcare Company (ACHC) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ACHC